Iversun 12 mg

When prescribed for a susceptible parasitic infection, Iversun 12 mg helps remove the parasite responsible for the illness. Its treatment benefits include:

• Treating susceptible intestinal worms

• Controlling onchocerciasis infection

• Reducing parasite-related skin symptoms

• Treating selected mite or lice infestations

• Providing an oral treatment option when appropriate

Successful treatment can reduce symptoms such as itching, rash, abdominal discomfort and other problems caused by the diagnosed parasite. Follow-up testing or repeat treatment is necessary for some infections.

Laboratory cancer findings and ongoing clinical research provide a reason for continued scientific investigation. However, they do not confirm a cancer-treatment benefit in people. Research involving COVID-19 has also not established ivermectin as an effective antiviral treatment.

Ivermectin attaches to specialised chloride channels found in the nerve and muscle cells of susceptible parasites. This increases the movement of chloride ions into their cells, interfering with normal nerve signals.

The affected parasite becomes paralysed and eventually dies. The body can then remove it. Ivermectin acts selectively on parasites at prescribed doses because these particular channels are not present in the same form in humans.

In COVID-19 research, early laboratory studies examined possible antiviral activity. However, the concentrations producing these effects were difficult to achieve safely in the human body, and clinical studies did not demonstrate a meaningful overall benefit.

Cancer researchers are investigating whether ivermectin can affect cancer-cell growth, programmed cell death, signalling pathways and the tumour immune environment. Most findings remain preclinical, and human safety and effectiveness have not been established for cancer treatment.

The correct ivermectin dose is based on body weight and the diagnosed parasitic infection. One 12 mg tablet is not automatically the correct dose for every patient.

For intestinal strongyloidiasis, ivermectin is commonly prescribed as a single dose of approximately 200 micrograms per kilogram of body weight. For onchocerciasis, treatment commonly uses approximately 150 micrograms per kilogram, with follow-up or repeat treatment determined by the healthcare professional or treatment programme.

Take the prescribed amount with water on an empty stomach unless different instructions are provided. If the product is supplied as a dispersible tablet, follow the instructions on the package or prescription for dissolving or swallowing it.

There is no established Iversun 12 mg dosage for COVID-19 or cancer. Do not copy online protocols, clinical-trial schedules or another person’s dose. The tablet strength does not confirm that one tablet is suitable for a particular condition.

Common Side Effects: Iversun 12 mg can cause nausea, diarrhoea, stomach discomfort, dizziness, sleepiness, headache, tiredness, itching, rash or mild swelling. Treatment for onchocerciasis can also produce an inflammatory reaction as dying parasites release substances into the body. This can cause fever, itching, rash, tender lymph nodes, joint pain or swelling. Contact the prescriber if these symptoms are persistent or difficult to manage.

Serious Side Effects: Obtain urgent medical help for fainting, severe dizziness, confusion, difficulty walking, seizures, breathing difficulty, facial or throat swelling, severe skin peeling or blistering, yellow skin or eyes, dark urine or unusual bleeding. People with heavy Loa loa infection can develop serious neurological complications after ivermectin treatment and require specialist assessment.

Iversun 12 mg requires medical assessment before use. Particular caution applies to:

• People allergic to ivermectin

• Pregnant women without medical approval

• Breastfeeding women without medical assessment

• Children weighing less than 15 kg

• People with suspected Loa loa infection

• People with significant liver disease

• People with serious neurological conditions

• People taking warfarin

• People self-treating COVID-19 or cancer

Tell the doctor or pharmacist about every prescription medicine, supplement and herbal product being used.

Important combinations requiring medical review include:

• Warfarin and other anticoagulants

• Sedatives and sleeping medicines

• Other antiparasitic medicines

• Chemotherapy medicines

• Immunotherapy medicines

• Prescribed antiviral medicines

• Liver-affecting medicines

• Herbal products and supplements

Ivermectin has been associated with an increased blood-clotting test result called INR in people taking warfarin. Additional monitoring can therefore be required.

Do not combine Iversun with an online COVID-19 or cancer protocol without discussing every ingredient with the treating healthcare team.

• Keep Iversun 12 mg in its original packaging.

• Follow the temperature stated on the supplied pack.

• Store it in a cool and dry place.

• Protect it from heat, moisture and sunlight.

• Keep it away from children and pets.

• Do not use damaged or discoloured tablets.

• Check the batch number and expiry date before use.

• Dispose of expired tablets according to local requirements.